Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Tutt, Andrew ^a,b   Wang, Alice ^c   Rowland, Charles ^c   Gillett, Cheryl ^d   Lau, Kit ^c   Chew, Karen ^e   Dai, Hongyue ^f   Kwok, Shirley ^c   Ryder, Kenneth ^b   Shu, Henry ^c   Springall, Robert ^d   Cane, Paul ^g   McCallie, Blair ^c   Kam Morgan, Lauren ^h   Anderson, Steve ^h   Buerger, Horst ⁱ   Gray, Joe ^j   Bennington, James ^k   Esserman, Laura ^l   Hastie, Trevor ^m   Broder, Samuel ^c   Sninsky, John ⁱ   Brandt, Burkhard ⁱ   Waldman, Fred ^e,k   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c CELERA   (United States)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROSETTA INPHARMATICS   (United States)

^g ST THOMAS HOSPITAL   (United Kingdom)

^h LABORATORY CORPORATION OF AMERICA   (United States)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^k CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN; CENTROMERE PROTEIN A; CYCLIN B1; DIAPHANOUS HOMOLOGY 3; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE; ONCOPROTEIN; ORIGIN RECOGNITION COMPLEX SUBUNIT 6 HOMOLOGY LIKE YEAST; PROLINE RICH 11; PROTEIN MYBL2; PROTEIN PKMYTI; RAC GTPASE ACTIVATING PROTEIN 1; REPLICATION FACTOR C; TAMOXIFEN; THYMIDINE KINASE 1; UBIQUITIN CONJUGATING ENZYME E2S; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FOLLOW UP; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; LABELING INDEX; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; OVERALL SURVIVAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; AGED; BREAST TUMOR; CHI SQUARE DISTRIBUTION; FEMALE; GENETICS; KAPLAN MEIER METHOD; LYMPH NODE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PROPORTIONAL HAZARDS MODEL; ROC CURVE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 59349092369     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-339     Document Type: Article

References (52)

1. van 't Veer LJ Dai H Vijver van de MJ He YD Hart AA Mao M Peterse HL Kooy van der K Marton MJ Witteveen AT Schreiber GJ Kerkhoven RM Roberts C Linsley PS Bernards R Friend SH Gene expression profiling predicts clinical outcome of breast cancer Nature 2002, 415:530-536. 10.1038/ 415530a 11823860
2. van de Vijver MJ He YD van't Veer LJ Dai H Hart AA Voskuil DW Schreiber GJ Peterse JL Roberts C Marton MJ Parrish M Atsma D Witteveen A Glas A Delahaye L Velde van der T Bartelink H Rodenhuis S Rutgers ET Friend SH Bernards R A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967 12490681
3. Buyse M Loi S van't Veer L Viale G Delorenzi M Glas AM d'Assignies MS Bergh J Lidereau R Ellis P Harris A Bogaerts J Therasse P Floore A Amakrane M Piette F Rutgers E Sotiriou C Cardoso F Piccart MJ TRANSBIG Consortium Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 2006, 98:1183-1192. 16954471
4. Paik S Shak S Tang G Kim C Baker J Cronin M Baehner FL Walker MG Watson D Park T Hiller W Fisher ER Wickerham DL Bryant J Wolmark N A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588 15591335
5. Paik S Tang G Shak S Kim C Baker J Kim W Cronin M Baehner FL Watson D Bryant J Costantino JP Geyer CE Jr Wickerham DL Wolmark N Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 2006, 24:3726-32. 10.1200/JCO.2005.04.7985 16720679
6. Goetz MP Suman VJ Ingle JN Nibbe AM Visscher DW Reynolds CA Lingle WL Erlander M Ma XJ Sgroi DC Perez EA Couch FJ A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen Clin Cancer Res 2006, 12:2080-2087. 10.1158/1078-0432.CCR-05-1263 16609019
7. Ma XJ Hilsenbeck SG Wang W Ding L Sgroi DC Bender RA Osborne CK Allred DC Erlander MG The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer J Clin Oncol 2006, 24:4611-4619. 10.1200/ JCO.2006.06.6944 17008703
8. Jansen MP Sieuwerts AM Look MP Ritstier K Meijer-van Gelder ME van Staveren IL Klijn JG Foekens JA Berns EM HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: A retrospective study J Clin Oncol 2007, 25:662-668. 10.1200/JCO.2006.07.3676 17308270
9. Wang Y Klijn JG Zhang Y Sieuwerts AM Look MP Yang F Talantov D Timmermans M Meijer-van Gelder ME Yu J Jatkoe T Berns EM Atkins D Foekens JA Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 2005, 365:671-679. 15721472
10. Foekens JA Atkins D Zhang Y Sweep FC Harbeck N Paradiso A Cufer T Sieuwerts AM Talantov D Span PN Tjan-Heijnen VC Zito AF Specht K Hoefler H Golouh R Schittulli F Schmitt M Beex LV Klijn JG Wang Y Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer J Clin Oncol 2006, 24:1665-1671. 10.1200/JCO.2005.03.9115 16505412
11. Desmedt C Piette F Loi S Wang Lallemand F Haibe-Kains B Viale GY Delorenzi M Zhang Y d'Assignies MS Bergh J Lidereau R Ellis P Harris AL Klijn JG Foekens JA Cardoso F Piccart MJ Buyse M Sotiriou C TRANSBIG Consortium Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series Clin Cancer Res 2007, 13:3207-14. 10.1158/ 1078-0432.CCR-06-2765 17545524
12. Chang HY Nuyten DS Sneddon JB Hastie T Tibshirani R Sørlie T Dai H He YD van't Veer LJ Bartelink H Rijn van de M Brown PO Vijver van de MJ Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci USA 2005, 102:3738-3743. 548329 15701700 10.1073/pnas.0409462102
13. Fan C Oh DS Wessels L Weigelt B Nuyten DS Nobel AB van't Veer LJ Perou CM Concordance among gene-expression-based predictors for breast cancer N Engl J Med 2006, 355:560-569. 10.1056/NEJMoa052933 16899776
14. Dai H van't Veer L Lamb J He YD Mao M Fine BM Bernards R Vijver van de M Deutsch P Sachs A Stoughton R Friend S A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients Cancer Res 2005, 65:4059-4066. 10.1158/0008-5472.CAN-04-3953 15899795
15. West M Blanchette C Dressman H Huang E Ishida S Spang R Zuzan H Olson JA Jr Marks JR Nevins JR Predicting the clinical status of human breast cancer by using gene expression profiles Proc Natl Acad Sci USA 2001, 98:11462-11467. 58752 11562467 10.1073/pnas.201162998
16. World Health Organization, Geneva, Switzerland. Histological typing of breast tumours Tumori 1982, 68:181. 6291202
17. Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long term follow-up Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x 1757079
18. Rogge L Bianchi E Biffi M Bono E Chang SY Alexander H Santini C Ferrari G Sinigaglia L Seiler M Neeb M Mous J Sinigaglia F Certa U Transcript imaging of the development of human T helper cells using oligonucleotide arrays Nat Genet 2000, 25:96-101. 10.1038/75671 10802665
19. Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 2001, 25:402-408. 10.1006/meth.2001.1262 11846609
20. Troyanskaya O Cantor M Sherlock G Brown P Hastien T Tibshirani R Botstein D Altman RB Missing value estimation methods for DNA microarrays Bioinformatics 2001, 17:520-552. 10.1093/bioinformatics/ 17.6.520 11395428
21. Bair E Tibshirani R Semi-supervised methods to predict patient survival from gene expression data PloS Biology 2004, 2:0511-0522. 10.1371/ journal.pbio.0020108
22. Bair E Hastie T Debashis P Tibshirani R Prediction by supervised principal components J Am Stat Assoc 2006, 101:119-137. 10.1198/ 016214505000000628
23. Hastie TJ Narasimhan B Tibshirani RJ PAM -Prediction Analysis of Microarrays Software online 2005 http://www-stat.stanford.edu/~tibs/PAM/ index.html
24. Cox DR Regression models and life tables (with discussion) J Royl Stat Soc 1972, B34:187-220.
25. Tibshirani R Regression shrinkage and selection via the lasso J Roy Stat Soc B 1996, 58:267-88.
26. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 1958, 53:457-481. 10.2307/228186
27. Collett D Modeling Survival Data in Medical Research London: Chapman and Hall 1994
28. Harrell F Regression Modeling Strategies: With applications to linear models, logistic regression, and survival analysis New York: Springer-Verlag 2001
29. SAS software, version 9.1 SAS Institute Inc., Cary, NC, USA 2001
30. R: A Language and Environment for Statistical Computing R Devleopment Core Team, R Foundation for Statistical Computing, Vienna Australia 2007 http://www.R-project.org ISBN 3-900051-07-0
31. Heagerty PJ Lumley T Pepe MS Time-Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker Biometrics 2000, 56:337-344. 10.1111/j.0006-341X.2000.00337.x 10877287
32. Akritas MG Nearest neighbor estimation of a bivariate distribution under random censoring Annals of Statistics 1994, 22:1299-1327. 10.1214/aos/ 1176325630
33. Efron B Tibshirani RJ An Introduction to the Bootstrap Chapman and Hall/ CRC Press 1993
34. Flanagan MB Dabbs DJ Brufsky AM Beriwal S Bhargava R Histopathologic variables predict Oncotype DXtrade mark Recurrence Score Mod Pathol 2008, 21:1255-61. 17906617 10.1038/modpathol.2008.54
35. Adjuvant! Online http://www.adjuvantonline.com/index.jsp
36. Edén P Ritz C Rose C Fernö M Peterson C "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers Eur J Cancer 2004, 40:1837-41. 10.1016/j.ejca.2004.02.025 15288284
37. Vincent-Salomon A Rousseau A Jouve M Beuzeboc P Sigal-Zafrani B Fréneaux P Rosty C Nos C Campana F Klijanienko J Al Ghuzlan A Sastre-Garau X Breast Cancer Study Group Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy Eur J Cancer 2004, 40:1502-1508. 10.1016/j.ejca.2004.03.014 15196533
38. Burcombe R Wilson GD Dowsett M Khan I Richman PI Daley F Detre S Makris A Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer Breast Cancer Res 2006, 8:R31. 1557736 16790076 10.1186/bcr1508
39. Colozza M Azambuja E Cardoso F Sotiriou C Larsimont D Piccart MJ Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol 2005, 16:1723-1739. 10.1093/annonc/ mdi352 15980158
40. Dowsett M Smith IE Ebbs SR Dixon JM Skene A A'Hern R Salter J Detre S Hills M Walsh G IMPACT Trialists Group Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 2007, 99:167-170. 10.1093/jnci/djk020 17228000
41. Miller WR Dixon JM Macfarlane L Cameron D Anderson TJ Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen Eur J Cancer 2003, 39:462-468. 10.1016/ S0959-8049(02)00600-7 12751376
42. Potemski P Pluciennik E Bednarek AK Kusinska R Kubiak R Jesionek-Kupnicka D Watala C Kordek R Ki-67 expression in operable breast cancer: A comparative study of immunostaining and a real-time RT-PCR assay Pathol Res Pract 2006, 202:491-495. 10.1016/ j.prp.2006.02.005 16678980
43. Tan PH Bay BH Yip G Selvarajan S Tan P Wu J Lee CH Li KB Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death Mod Patho 2005, 18:374-381. 10.1038/modpathol.3800254
44. de Azambuja E Cardoso F de Castro G Jr Colozza M Mano MS Durbecq V Sotiriou C Larsimont D Piccart-Gebhart MJ Paesmans M Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients Br J Cancer 2007, 96:1504-1513. 10.1038/ sj.bjc.6603756 17453008
45. Whitfield ML George LK Grant GD Perou CM Common markers of proliferation Nat Rev Cancer 2006, 6:99-106. 10.1038/nrc1802 16491069
46. Miller LD Smeds J George J Vega VB Vergara L Ploner A Pawitan Y Hall P Klaar S Liu ET Bergh J An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival Proc Natl Acad Sci USA 2005, 102:13550-13555. 1197273 16141321 10.1073/pnas.0506230102
47. Pai SI Lin YY Macaes B Meneshian A Hung CF Wu TC Prospects of RNA interference therapy for cancer Gene Ther 2006, 13:464-477. 10.1038/ sj.gt.3302694 16341059
48. Akinc A Zumbuehl A Goldberg M Leshchiner ES Busini V Hossain N Bacallado SA Nguyen DN Fuller J Alvarez R Borodovsky A Borland T Constien R de Fougerolles A Dorkin JR Narayanannair Jayaprakash K Jayaraman M John M Koteliansky V Manoharan M Nechev L Qin J Racie T Raitcheva D Rajeev KG Sah DW Soutschek J Toudjarska I Vornlocher HP Zimmermann TS Langer R Anderson DG A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nat Biotechnol 2008, 26:561-569. 10.1038/nbt1402 18438401
49. Devi GR siRNA-based approaches in cancer therapy Cancer Gene Ther 2006, 13:819-829. 10.1038/sj.cgt.7700931 16424918
50. Hayes DF Prognostic and predictive factors revisited Breast 2005, 14:493-499. 10.1016/j.breast.2005.08.023 16239111
51. Esteva FJ Sahin AA Cristofanilli M Coombes K Lee SJ Baker J Cronin M Walker M Watson D Shak S Hortobagyi GN Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy Clin Cancer Res 2005, 11:3315-3319. 10.1158/1078-0432.CCR-04-1707 15867229
52. Carey LA Perou CM Livasy CA Dressler LG Cowan D Conway K Karaca G Troester MA Tse CK Edmiston S Deming SL Geradts J Cheang MC Nielsen TO Moorman PG Earp HS Millikan RC Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492 16757721